Cancer
Stomach cancer
胃癌
Tumours or cancer of the stomach.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 218
- cities
- 67
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 49% of the world's English-language research papers on stomach cancer, 2021–2025 (38% in 2016–2020), and 33% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
218 hospitals in 67 cities
Order: papers led on stomach cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 11 papers or 1 trial on stomach cancer, or was a site in 8 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens stomach cancer in that city. 57 more cities are in the menu below.
- 223 papers led
- 199 papers led
- 168 papers led
- 166 papers led
- 140 papers led
- 134 papers led
- 131 papers led
- 127 papers led
- 113 papers led
- 109 papers led
- 108 papers ledNo open trial led
- 107 papers led
- 106 papers led
- 105 papers led
- 105 papers led
- 104 papers led
- 103 papers led
- 98 papers ledNo open trial led
- 96 papers led
- 90 papers led
- 88 papers led
- 84 papers ledNo open trial led
- 80 papers led
- 78 papers led
- 78 papers led
- 76 papers ledNo open trial led
- 76 papers led
- 73 papers led
- 69 papers led
- 65 papers ledNo open trial led
- 65 papers led
- 63 papers led
- 59 papers ledNo open trial led
- 59 papers led
- 58 papers led
- 57 papers ledNo open trial led
- 55 papers led
- 54 papers ledNo open trial led
- 52 papers ledNo open trial led
- 52 papers ledNo open trial led
- 47 papers led
- 46 papers ledNo open trial led
- 45 papers led
- 45 papers ledNo open trial led
- 45 papers led
- 45 papers led
- 44 papers ledNo open trial led
- 41 papers led
- 40 papers led
- 39 papers ledNo open trial led
- 38 papers led
- 38 papers led
- 37 papers ledNo open trial led
- 37 papers ledNo open trial led
- 35 papers ledNo open trial led
- 35 papers ledNo open trial led
- 35 papers ledNo open trial led
- 33 papers led
- 33 papers ledNo open trial led
- 32 papers ledNo open trial led
- 32 papers ledNo open trial led
- 31 papers ledNo open trial led
- 31 papers led
- 31 papers led
- 31 papers led
- 30 papers ledNo open trial led
- 30 papers ledNo open trial led
- 29 papers led
- 29 papers ledNo open trial led
- 29 papers ledNo open trial led
- 29 papers led
- 28 papers ledNo open trial led
- 27 papers led
- 27 papers ledNo open trial led
- 27 papers led
- 27 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers led
- 26 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers led
- 25 papers led
- 24 papers ledNo open trial led
- 24 papers led
- 24 papers ledNo open trial led
- 24 papers led
- 24 papers ledNo open trial led
- 24 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers ledNo open trial led
- 23 papers led
- 22 papers ledNo open trial led
- 22 papers led
- 22 papers led
- 22 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers led
- 21 papers led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 21 papers led
- 21 papers led
- 20 papers ledNo open trial led
- 20 papers led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 19 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 18 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 9 papers led
- 9 papers led
- 9 papers ledNo open trial led
- 9 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 59
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 378 papers led6 hospitals
- 323 papers led6 hospitals
- 316 papers led6 hospitals
- 283 papers led6 hospitals
- 281 papers led6 hospitals
- 276 papers led6 hospitals
- 255 papers led6 hospitals
- 210 papers led6 hospitals
- 203 papers led6 hospitals
- 198 papers led6 hospitals
- 180 papers led6 hospitals
- 179 papers led6 hospitals
- 173 papers led6 hospitals
- 170 papers led6 hospitals
- 162 papers led6 hospitals
- 153 papers led6 hospitals
- 146 papers led6 hospitals
- 145 papers led6 hospitals
- 143 papers led6 hospitals
- 141 papers led6 hospitals
- 140 papers led1 hospital
- 136 papers led6 hospitals
- 132 papers led6 hospitals
- 125 papers led6 hospitals
- 113 papers led6 hospitals
- 113 papers led3 hospitals
- 107 papers led6 hospitals
- 107 papers led1 hospital
- 106 papers led1 hospital
- 104 papers led3 hospitals
- 101 papers led6 hospitals
- 97 papers led5 hospitals
- 84 papers led6 hospitals
- 77 papers led6 hospitals
- 77 papers led6 hospitals
- 72 papers led6 hospitals
- 68 papers led6 hospitals
- 59 papers led6 hospitals
- 56 papers led5 hospitals
- 56 papers led6 hospitals
- 55 papers led4 hospitals
- 49 papers led5 hospitals
- 41 papers led6 hospitals
- 39 papers led1 hospital
- 39 papers led3 hospitals
- 37 papers led4 hospitals
- 34 papers led6 hospitals
- 33 papers led6 hospitals
- 31 papers led1 hospital
- 30 papers led1 hospital
- 29 papers led6 hospitals
- 27 papers led6 hospitals
- 26 papers led1 hospital
- 25 papers led1 hospital
- 24 papers led6 hospitals
- 15 papers led1 hospital
- 14 papers led3 hospitals
- 9 papers led1 hospital
- 6 papers led2 hospitals
open trials on stomach cancer in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 315 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07221149
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai
- RecruitingSingle-port Robotic Radical Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07237126
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingSHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07311408
Age 18 years to Not stated (registered criteria)
Led by Liaoning Provincial Cancer HospitalShenyang
- RecruitingA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07315750
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07351474
Age 65 years to 100 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07354711
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07362186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07392892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan
- RecruitingDeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07401173
Age 18 years to 85 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingMultimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07401199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan
- RecruitingFull-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07401303
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingDigital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07441850
Age 18 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingSHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07464756
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDisitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07474324
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingIBI343 in Combination Therapy for Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07483554
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07492615
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07517107
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07522151
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07523529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingAI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07525765
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07537348
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingSafety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07537361
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07551362
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingAI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07551466
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingOral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07552402
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan
- RecruitingLM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07556640
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingEvaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07600125
Age 18 years to Not stated (registered criteria)
Led by Xijing Hospital; 2 listed hospitals as study sitesDalian, Qingdao, Xi'an
- RecruitingLaparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07615374
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingHIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07621484
Age 18 years to 75 years (registered criteria)
Led by Changzheng HospitalShanghai
- RecruitingComparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07635836
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingTwo-component Radiology-guided Autonomous Cascade Engine (TRACE)
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07651644
Age not stated (registered criteria)
Led by Liaoning Cancer Hospital & InstituteShenyang
- RecruitingA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07673887
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingChemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07689851
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan
- RecruitingPhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07700979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-06
- Registry
- NCT07707531
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingClinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07708012
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingTEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07714980
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai
- RecruitingRetrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07747688
Age 18 years to 90 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingCT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07776067
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07788196
Age 18 years to Not stated (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingImage-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07835087
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingSilent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07849608
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingAnti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07855640
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingLECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07857668
Age 20 years to 80 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Recruiting68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07914764
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingSystemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06519591
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06685887
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06760819
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai
- RecruitingQL1706 Combined With SOX Used in Theperioperative Treatment
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06766305
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06769425
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingBC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06773312
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingRobotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT06791538
Age 18 years to 75 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingTislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT06793917
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingCOMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06796764
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingNanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06830018
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06873659
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an
- RecruitingExploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06881511
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingctDNA-MRD Monitoring After Resection in Gastric Cancer
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06893133
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingMetabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06915389
Age 18 years to 80 years (registered criteria)
Led by Qinghai Red Cross HospitalXining
- RecruitingNeoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06925243
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingReal-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06940102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingClinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06945718
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingSafety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT06947291
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingNeoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06949033
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingBovine Reinforcement in Stomach, Colorectal and Lung Operation
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06968221
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingInvestigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT06979895
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteXi'an
- RecruitingCorrelation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07003334
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingConversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07007182
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingVenetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07012447
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07023315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang
- RecruitingIBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07025889
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPerioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07026149
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingFeasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07029269
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an
- RecruitingA Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07032961
Age 45 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingClinical Evaluation of GRAPE Model for Gastric Cancer Screening
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07067983
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07068529
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07069842
Age 18 years to 75 years (registered criteria)
Led by Changzhi People's Hospital, Changzhi Medical CollegeChangzhi
- RecruitingA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07070232
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07076979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingMulticenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07078136
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingShenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07098026
Age 18 years to 75 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07102901
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou
- RecruitingA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07103668
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingDevelopment and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07104214
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07110571
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shijiazhuang
- RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07114601
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingMultimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07124754
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingAssessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07127822
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingThe Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07139418
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT07142122
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingNeoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07165847
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- RecruitingSafety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
- Phase
- Early phase 1
- Started
- 2025-10
- Registry
- NCT07166263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingCombination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07175155
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou
- RecruitingThe PRE-VAIL Study
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07176624
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingThe Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07183150
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingConversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07194005
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07212933
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07213791
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07250347
Age 18 years to 85 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDistribution Characteristics of Helicobacter Pylori
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07253948
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07263386
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingPhase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07277439
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingIparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07289997
Age 18 years to Not stated (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- RecruitingNovel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07294638
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingPDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07294664
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingClinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07298200
Age 18 years to 70 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingClinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07301814
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07307560
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingIparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07315854
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingPerioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07325630
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingAdebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT07353684
Age 18 years to 75 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07359586
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAdjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07366528
Age 18 years to 80 years (registered criteria)
Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai
- RecruitingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07371663
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou
- RecruitingSafety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07392346
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRCT of EFTR Versus STER for GIST Treatment
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07411118
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSingle-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07586384
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA IIT Study of 177Lu-DOTA-SNA040
- Phase
- Early phase 1
- Started
- 2025-11
- Registry
- NCT07595237
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTAIC FOLFOX for Locally Advanced G/GEJA
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07655024
Age 18 years to Not stated (registered criteria)
Led by Guang'anmen HospitalBeijing
- RecruitingThe Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07757165
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07770113
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou University; 1 listed hospital as study siteLuoyang, Zhengzhou
- RecruitingPredicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07824479
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07867392
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCandonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07920224
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingExploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT05812287
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingFeasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT05892289
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06123494
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
- RecruitingNKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06134960
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingLenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06157996
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingAK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06196697
Age 18 years to 75 years (registered criteria)
Led by Harbin Medical University HospitalHarbin
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingEarly Detection and Post-operative Monitoring of Gastric Cancer
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06232395
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06300879
Age 18 years to 75 years (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingEffectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06306755
Age 50 years to 69 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingMetronomic Capecitabine in Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06313567
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingSurvival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06338683
Age 18 years to 80 years (registered criteria)
Led by Qinghai Red Cross HospitalXining
- RecruitingConcurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06341595
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingFecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06346093
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingFMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06405113
Age 18 years to 80 years (registered criteria)
Led by Changzhou No.2 People's HospitalChangzhou
- RecruitingA Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06415669
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingFruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06417892
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingResearch on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06429891
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingEfficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06461910
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingStapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06464978
Age 18 years to 85 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingSynergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06468280
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06469944
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou
- RecruitingShort Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06487429
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06500052
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-08
- Registry
- NCT06504732
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang
- RecruitingA Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06506292
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingPerioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06510010
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingPreliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06543108
Age 18 years to 90 years (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06555471
Age 75 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDisitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06560528
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingDisitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06572319
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingImmune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06580574
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingProximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06597227
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingThe Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06597526
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingImmunoPET Imaging of Pancreatic Cancer
- Phase
- N/A
- Started
- 2024-11
- Registry
- NCT06602037
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingStudy of IBI363 in Patients with Advanced First-line Gastric Cancer
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06610799
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingCadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06650332
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingIMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06662110
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingApplication of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06679244
Age 18 years to 80 years (registered criteria)
Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingIntegrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06702891
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingTrifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06711471
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingEffect of Premedication With Pronase on Mucosal Cleanliness During EGD
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06713421
Age 18 years to 70 years (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingTarget-specific immunoPET Imaging of Digestive System Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715839
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingAnalysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06728878
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAnalysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06728891
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingFirst-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06730373
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo
- RecruitingExploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06736847
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingXELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Registry
- NCT06742411
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06748352
Age 18 years to 80 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingMCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06748690
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingIntraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06759064
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingA Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06760858
Age 18 years to 80 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingA Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Registry
- NCT06776770
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital CAMS – ShenzhenShenzhen
- RecruitingA First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06783569
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang
- RecruitingThe Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06786169
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingFluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06788548
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingClinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06791083
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingLow-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06791148
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower HospitalNanjing
- RecruitingStudy of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06821048
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06826079
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingEnergy CT in Imaging and Diagnosis of Gastric Cancer
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06869694
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingThe Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06881043
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingRobotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06895447
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingThe Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06929949
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingCDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06937567
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPost-operative Monitoring of Gastric Cancer
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT07026240
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
- Phase
- N/A
- Started
- 2024-11
- Registry
- NCT07056010
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEffect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT07119463
Age 18 years to 80 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingAdebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT07309185
Age 18 years to 75 years (registered criteria)
Led by Shandong Tumor HospitalJinan
- RecruitingFruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-02
- Registry
- NCT07334431
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingThe Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT07400354
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07547787
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingHelicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT07724496
Age 18 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingValidating a Medical AI Fine-Tuning Platform for Major Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07795645
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingTEAS for Gastrectomy Recovery
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT07898293
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai
- RecruitingA Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingPhase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05319639
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingTransarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
- Phase
- Phase 3
- Started
- 2023-03
- Registry
- NCT05593458
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPh1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05671822
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05687357
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan
- RecruitingTislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-05
- Registry
- NCT05699655
Age 18 years to 75 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingPrediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05722275
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou
- RecruitingStudy of Comparing of With and Without Sequential Therapy of S-1
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05813015
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05918094
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05934331
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT05938309
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingThe Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT05956847
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingAdjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT05975749
Age 20 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06008054
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06023758
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- RecruitingA Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
- Phase
- N/A
- Started
- 2023-07
- Registry
- NCT06042998
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingNeoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-10
- Registry
- NCT06054906
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingThe Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06081647
Age 18 years to 60 years (registered criteria)
Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai
- RecruitingRadiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT06121700
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingClinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Registry
- NCT06126406
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu
- RecruitingA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Registry
- NCT06131840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06155383
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou
- RecruitingA Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
- Phase
- N/A
- Started
- 2023-11
- Registry
- NCT06158919
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT06161207
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06177041
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingAtrophic Gastritis Predicts the Risk of Gastric Cancer
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06203327
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
- Phase
- N/A
- Started
- 2023-01
- Registry
- NCT06277024
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Recruitinga Single-arm, Single-center, Open Clinical Study
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT06431100
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingNeoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT06451211
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-04
- Registry
- NCT06508307
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingThe Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT06702683
Age 18 years to Not stated (registered criteria)
Led by Zhongda Hospital, Southeast UniversityNanjing
- RecruitingStudy on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06735105
Age 18 years to 80 years (registered criteria)
Led by Yunnan Cancer HospitalKunming
- RecruitingA Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06774222
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingPD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Registry
- NCT06792162
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingDocetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT04840264
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05262491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
- RecruitingThe Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
- Phase
- N/A
- Started
- 2022-01
- Registry
- NCT05323929
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingDetection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Phase
- Not given
- Started
- 2022-03
- Registry
- NCT05347524
Age 18 years to 74 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2022-06
- Registry
- NCT05365581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2022-04
- Registry
- NCT05427383
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingOGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Phase
- N/A
- Started
- 2022-09
- Registry
- NCT05450835
Age 18 years to 75 years (registered criteria)
Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang
- RecruitingXELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2022-03
- Registry
- NCT05494060
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingDual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2022-08
- Registry
- NCT05494086
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingThe Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05536102
Age 18 years to 75 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingLaparoscopic vs Open Total Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05537129
Age 20 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingClinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05618821
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingTreatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05620732
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingLaparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05871099
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- RecruitingFirst-Line and Neoadjuvant Immunotherapy for Gastric Cancer
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT06727981
Age 18 years to 100 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingOxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
- Phase
- Phase 3
- Started
- 2021-01
- Registry
- NCT04483076
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingMulticenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT04710758
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingComparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
- Phase
- Not given
- Started
- 2021-05
- Registry
- NCT04809025
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT04843215
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingRelationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
- Phase
- Not given
- Started
- 2021-05
- Registry
- NCT04850729
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingToripalimab Plus FLOT in Locally Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2021-06
- Registry
- NCT04891016
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04997837
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGastric Cancer Marker Detection and Its Kit Development
- Phase
- Not given
- Started
- 2021-01
- Registry
- NCT05010863
Age not stated (registered criteria)
Led by Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingPD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2021-09
- Registry
- NCT05033392
Age 18 years to 79 years (registered criteria)
Led by Shenzhen People's HospitalShenzhen
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMulti-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05508126
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingProximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer
- Phase
- N/A
- Started
- 2021-01
- Registry
- NCT05514769
Age 18 years to 85 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingDevelopment of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
- Phase
- Not given
- Started
- 2021-06
- Registry
- NCT06078930
Age 18 years to 90 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCarilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2021-03
- Registry
- NCT07320586
Age 18 years to 75 years (registered criteria)
Led by Shandong Tumor HospitalJinan
- RecruitingSamples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT03972956
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingReduced Port Laparoscopic Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2020-03
- Registry
- NCT04295473
Age 18 years to 90 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingAjuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
- Phase
- N/A
- Started
- 2020-07
- Registry
- NCT04688801
Age 25 years to 80 years (registered criteria)
Led by Second Hospital of Shandong UniversityJinan
- RecruitingPrediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2020-09
- Registry
- NCT05140746
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingLinear Stapler Versus Circular Stapler in Esophagojejunostomy
- Phase
- N/A
- Started
- 2020-01
- Registry
- NCT05360069
Age 18 years to 90 years (registered criteria)
Led by Nanchong Central HospitalNanchong
- RecruitingS-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03941561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu
- RecruitingPaclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
- Phase
- N/A
- Started
- 2019-09
- Registry
- NCT04047953
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingComparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
- Phase
- Not given
- Started
- 2018-10
- Registry
- NCT03716089
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- RecruitingApatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2017-09
- Registry
- NCT03219593
Age 65 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu
- RecruitingPredicting Gastric Cancer Response to Chemo With Multimodal AI Model
- Phase
- Not given
- Started
- 2013-02
- Registry
- NCT06451393
Age 20 years to 90 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingSintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT06365008
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingEsomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
- Phase
- Phase 4
- Started
- 2026-04
- Registry
- NCT07312370
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou
- Not yet recruitingClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07314203
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingRecurrence After Gastric and Intestinal Polyp Resection
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07314554
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou
- Not yet recruitingQL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07315035
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingRobotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07331454
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07333573
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingIBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07361991
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingPerioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07374250
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingMegestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07391826
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingClinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-09
- Registry
- NCT07394205
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingLDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07453875
Age 18 years to 75 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingEvaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07486310
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingComparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07507071
Age 18 years to 75 years (registered criteria)
Led by Changhai HospitalShanghai
- Not yet recruitingA Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07507526
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07508956
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruiting18F-FAPI PET/CT and MRI in Gastric Cancer
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07510867
Age 20 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingBeta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07511894
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingNon-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07554742
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingStomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07561073
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanning
- Not yet recruitingAdaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Registry
- NCT07603349
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingRetlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07610629
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07615907
Age 18 years to 80 years (registered criteria)
Led by Jinling HospitalNanjing
- Not yet recruitingTafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07621562
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingMannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07655661
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingNon-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07656740
Age not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingOne-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07664813
Age 18 years to Not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07669740
Age 15 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingZanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07685704
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingSacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07701681
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingProspective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07746830
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingHome-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07764523
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingAI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07782294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai
- Not yet recruitingA Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07784413
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingHigh-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07791979
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingTR115 in ARID1A-Mutated Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07793318
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07799649
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingSafety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07828899
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou
- Not yet recruitingExploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07872696
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07878221
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07902596
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou
- Not yet recruitingSND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-12
- Registry
- NCT07903857
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingEffect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
- Phase
- N/A
- Started
- 2026-11
- Registry
- NCT07904260
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingD2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07912606
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingNeoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07912957
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingMulti-center Prospective Validation of Real-Time AI-EGGIM System
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07915843
Age not stated (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingGK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07923396
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06464601
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingPreliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06741501
Age 18 years to 80 years (registered criteria)
Led by Northern Jiangsu People's HospitalYangzhou
- Not yet recruitingEndoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06759233
Age 18 years to 80 years (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingPredicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06853509
Age 45 years to Not stated (registered criteria)
Led by Huadong Hospital, Fudan UniversityShanghai
- Not yet recruitingFruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06871527
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingFruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06888037
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06944496
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06957977
Age 18 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- Not yet recruitingThe Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT06977386
Age 18 years to 80 years (registered criteria)
Led by Yunnan Cancer HospitalKunming
- Not yet recruitingNode-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06980389
Age 18 years to 75 years (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- Not yet recruitingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07014254
Age 18 years to 80 years (registered criteria)
Led by Xijing HospitalXi'an
- Not yet recruitingNeoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07018063
Age 16 years to 45 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingPD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07031011
Age 18 years to 75 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingOmega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07050524
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingPerioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT07068516
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingComparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07088744
Age 18 years to 80 years (registered criteria)
Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai
- Not yet recruitingAcupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
- Phase
- N/A
- Started
- 2025-08
- Registry
- NCT07098949
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou
- Not yet recruitingThe Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07139587
Age 18 years to 75 years (registered criteria)
Led by Hebei General HospitalShijiazhuang
- Not yet recruitingClinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07172503
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingFamily-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07183358
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingA Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07233850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingFeasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07257380
Age 18 years to 79 years (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- Not yet recruitingNovel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07276854
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingA Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07304258
Age 18 years to 75 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Not yet recruitingEffect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Phase
- Phase 4
- Started
- 2024-07
- Registry
- NCT05498766
Age 18 years to 75 years (registered criteria)
Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan
- Not yet recruitingEfficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06241469
Age 18 years to 80 years (registered criteria)
Led by Third Affiliated Hospital of Soochow UniversityChangzhou
- Not yet recruitingNeoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06310473
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingTislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06374901
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06421220
Age 18 years to 75 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Not yet recruitingConversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06454435
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingRC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06492317
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingProspective Observational Cohort Study
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06493448
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06496919
Age 18 years to 80 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingClinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
- Phase
- Phase 4
- Started
- 2024-07
- Registry
- NCT06499610
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- Not yet recruitingSurufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06531291
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06614751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- Not yet recruitingSHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06666166
Age 18 years to 75 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingComparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06748508
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingLaparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05890339
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingPerioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05970627
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo
- Not yet recruitingthe Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
- Phase
- N/A
- Started
- 2022-02
- Registry
- NCT05235932
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingThe Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
- Phase
- N/A
- Started
- 2022-04
- Registry
- NCT05356156
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingClinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05524974
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingClinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05610332
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingDragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Registry
- NCT04384601
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingTotal Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2021-03
- Registry
- NCT04795063
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Not yet recruitingEndoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- Phase
- N/A
- Started
- 2019-03
- Registry
- NCT03857737
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- Enrolling by invitationEarly Postoperative Intervention in Gastric Cancer Patients
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07444099
Age 18 years to 80 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Enrolling by invitationAnemia on Sublingual Microcirculation in GDFT
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07583927
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Enrolling by invitationNon-surgical Management After NIT for dMMR/MSI-H GC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07646574
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationRadiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06947096
Age 18 years to 80 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Enrolling by invitationAI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06957678
Age 18 years to 80 years (registered criteria)
Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang
- Enrolling by invitationPET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07023848
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationThe Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07023861
Age 15 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangnan UniversityWuxi
- Enrolling by invitationExplainable Machine Learning for Predicting Early Gastric Cancer
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07047937
Age not stated (registered criteria)
Led by Wenzhou Central HospitalWenzhou
- Enrolling by invitationAn Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07274579
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan
- Enrolling by invitationClinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Early phase 1
- Started
- 2025-05
- Registry
- NCT07356466
Age 18 years to 75 years (registered criteria)
Led by Fujian Medical University Union HospitalFuzhou
- Enrolling by invitationSafety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07488312
Age 18 years to 70 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
- Enrolling by invitationLaparoscopic Staging for Stage III Gastric Cancer
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07533825
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Enrolling by invitationEGPSS for Weight Management in an in Vivo Human Model
- Phase
- N/A
- Started
- 2024-07
- Registry
- NCT07186959
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Enrolling by invitationScreening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06776835
Age 18 years to 85 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- Enrolling by invitationProlonged Extubation in Gastric Cancer With OSA
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT07362706
Age 18 years to 85 years (registered criteria)
Led by Qilu Hospital of Shandong UniversityJinan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Guidelines for cancers and blood diseases (2022 edition)National Health Commission 国卫办医函〔2022〕104号, 2022-04-11
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.